Breaking News

Exacis Biotherapeutics Partners with CCRM

Includes a cash investment into Exacis by CCRM Enterprises Holdings Ltd., which will be used to fund operations.

Author Image

By: Charlie Sternberg

Associate Editor

Exacis Biotherapeutics Inc., a development-stage immuno-oncology company working to harness the immune system to cure cancer, has initiated a strategic partnership with Toronto-based Centre for Commercialization of Regenerative Medicine (CCRM) for specialty manufacturing services related to the development of Exacis’ innovative, iPSC-derived mRNA-engineered NK cell products to treat cancer.    The partnership also includes a cash investment into Exacis by CCRM Enterprises Holdings Ltd., the for-...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters